Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.

@article{Cohen2018Worldwide3P,
  title={Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.},
  author={Stanley B. Cohen and Jeffrey R. Curtis and Ryan Demasi and Yan Chen and Haiyun Fan and Arif Soonasra and Roy M Fleischmann},
  journal={Rheumatology and therapy},
  year={2018},
  volume={5 1},
  pages={283-291}
}
INTRODUCTION Post-marketing surveillance (PMS) is an integral part of monitoring adverse events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). An analysis of PMS reports was conducted to evaluate the safety of tofacitinib in a post-marketing setting. METHODS Worldwide tofacitinib PMS data received in the Pfizer safety database from November 6, 2012 (first marketing authorization of tofacitinib) to November 5… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Similar Papers

Loading similar papers…